Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.97%
+1.23%
-4.26%
-3.31%
SNY
Sanofi
$47.64
Chart
$50.12 (-4.95%)
$47.85 (-0.44%)
$54.95 (-13.30%)
$55.47 (-14.12%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.97%
+1.23%
-4.26%
-3.31%
SNY
Sanofi
Current Price
$47.64
Login to view Sanofi (SNY) recommendation from the last 90 days from financial news and social media.
Chart
$50.12 (-4.95%)
$47.85 (-0.44%)
$54.95 (-13.30%)
$55.47 (-14.12%)
SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
SNY Latest Analysis
Sanofi (SNY) Fell on Tariff Uncertainty.
Wed Sep 17, 2025
Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight. Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) |. DelveInsightThe recent approval of Sanofi'.s WAYRILZ has shifted the dynamics of the immune thrombocytopenic purpura market. This approval has also led to competition among other companies such as Principia Biopharma Novartis Takeda (Millennium Pharma
Mon Sep 15, 2025
Sanofis Tzield approved in China to delay type 1 diabetes progression.
Wed Sep 10, 2025
Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript.
Tue Sep 9, 2025
Sanofi upgraded at Morgan Stanley on potential of amlitelimab vs. Dupixent.
Mon Sep 8, 2025
Why Is Sanofi Stock Falling Thursday?. On Thursday ) stock tumbled after late-stage trial results for amlitelimab its potential successor to blockbuster eczema drug Dupixent failed to match investor expectations raising fresh doubts about the company’.s ability to sustain its dermatology franchise once .Results from the global COAST 1 phase 3 study showed that amlitelimab met all primary and key secondary endpoints demonstrating statistically significant and clinically meaningful skin clear
Thu Sep 4, 2025
Analysts postive on Nektar opportunity after Sanofi data.
Thu Sep 4, 2025
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors. French drugmaker ) stock fell sharply Thursday after late-stage trial results for amlitelimab its potential successor to blockbuster eczema drug Dupixent failed to match investor expectations raising fresh doubts about the company’.s ability to sustain its dermatology franchise once patent protections expire.Results from the global COAST 1 phase 3 study showed that amlitelimab met all primary and key secondary endpoints
Thu Sep 4, 2025
Sanofi Tumbles As New Eczema Drug Lags Dupixents Compelling Bar. Sanofi stock plummeted Thursday after the companys experimental eczema drug proved meaningfully inferior to Dupixent.The post Sanofi Tumbles As New Eczema Drug Lags Dupixent'.s '.Compelling Bar'. appeared first on Investor'.s Business Daily.
Thu Sep 4, 2025
Nektar Therapeutics stock jumps after Sanofis amlitelimab data disappoints.
Thu Sep 4, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings